Shai Lankry joined Gamida Cell’s leadership team as chief financial officer in April 2018, bringing more than a decade of senior management experience in finance to his role. Prior to joining Gamida Cell, Shai served as a finance director at West Pharmaceutical Services, Inc., where he led R&D and operation financials for the company’s Israeli subsidiary. Prior to West Pharmaceutical Services, he served as CFO and Israeli site manager of Macrocure, Ltd., where he played an integral role in the company’s NASDAQ Initial Public Offering process, raising a total capital of approximately $54 million. Before joining Macrocure, Shai was the finance director at Omrix Biopharmaceuticals, Ltd., a division of Ethicon Biosurgery, a Johnson & Johnson company, where in his most recent role, he managed the finance biologics organization at multiple sites worldwide. Earlier in his career, Shai served as a senior associate at PricewaterhouseCoopers in Tel Aviv.
Shai is a licensed Israeli CPA and holds an MBA from Tel Aviv University.